American Academy of Neurology Annual Meeting

, has been with the team since October 2019. Follow him on Twitter 

Articles

In total, 50% of patients eligible for device-aided therapies did not report having any discussion with providers about future device-aided therapies. 

Validated MANAGE-PD Tool May Identify Parkinson Disease Treatment Gaps

 joined the MJH Life Sciences team in October 2020. Follow her on Twitter 

The 2021 AAN Meeting Hot Topics plenary focused on neurological facets of COVID-19, and featured insight from Anthony Fauci, MD, of NIAID, and Walter Koroshetz, MD, of NINDS, among others. 

Treatment Disparities, Neurologic Complications Clarified by COVID-19 Neurological Research

Vascular neurology fellow at University of Maryland Medical Center

Videos

The vascular neurology fellow at the University of Maryland Medical Center discussed strategies to improve stroke care efficiency in women and African Americans. 

Mitigating Disparities in Stroke Rehabilitation Care: Sana Somani, MD, MBBS

An AAN session included presentations of research on the latest advancements and knowledge in neuromodulation for patients with these disorders. 

Deep Brain Stimulation Leads Advances in Neuromodulation for Movement Disorders

Director, Headache Medicine Fellowship Program, Associate Professor, Thomas Jefferson University

The associate professor and director of the Headache Medicine Fellowship Program at Thomas Jefferson University discussed 2 research projects she led presented at AAN 2021 on the efficacy and safety of fremanezumab.

Efficacy and Safety of Fremanezumab Further Displayed: Stephanie Nahas-Geiger, MD

Chief of Neurology, Ascension Saint Agnes

The chief of neurology at Ascension Saint Agnes discussed how providing an overview of patient-specific risk factors and mitigation can improve poststroke care. 

Implementing Patient-Specific Stroke Discharge Instructions: Marian LaMonte, MD, MSN, FAAN

Matt Hoffman, Senior Editor for NeurologyLive, has covered medical news for MJH Life Sciences, NeurologyLive’s parent company, since 2017. He hosts the NeurologyLive Mind Moments podcast, as well as Second Opinion on Medical World News. Follow him on Twitter 

Aducanumab currently sits before the FDA for review for the treatment of Alzheimer disease, with a PDUFA date set for June 7, 2021.

Aducanumab EMBARK Trial Seeks to Characterize Treatment Durability, Effects of Interruption

Alicia Bigica is the Associate Editorial Director for 

. Prior to joining MJH Life Sciences in 2019, she helped launch leading resources for medical news in the neurology and dermatology specialties. Follow her on Twitter 

Results from the ongoing clinical trial will help define clinical management guidelines for switching patients with relapsing MS on other disease-modifying therapies to siponimod. 

Switch to Siponimod Safe, Tolerable With No Washout, Study Finds

No stimulation adverse effects were reported, and patients on the MICC stimulation alone resulted in greater than 50% improvement in UPDRS motor scores.

Multiple Independent Current Control DBS Associated With Improved Outcomes in Parkinson Disease

Researchers from Ascension Saint Agnes improved compliance in their hospital in providing patient-specific, stroke-dedicated discharge instructions. 